title: Liver transplantation for hepatitis B: what is the best hepatitis B immune globulin/antiviral regimen?
abstract: 1. Prophylaxis using the combination of lamivudine and high-dose intravenous hepatitis B immunoglobulin (approximately 10,000 IU monthly) reduces the long-term risk of recurrence of hepatitis B in hepatitis B surface antigen-positive transplant recipients to 5% to 10%. However, this therapy is expensive and inconvenient for patients. 2. Recent studies have shown that similar results can be obtained, at far less cost, with much lower doses of intramuscular hepatitis B immune globulin (400-800 IU monthly) in combination with pretransplant and posttransplant lamivudine therapy. 3. The development of lamivudine resistance pre-transplant can lead to hepatic decompensation and increases the risk of posttransplant recurrence in patients receiving hepatitis B immune globulin/lamivudine prophylaxis. Newer nucleos(t)ide analogues with lower resistance rates such as entecavir, adefovir, and tenofovir should therefore replace lamivudine in hepatitis B prophylaxis. 4. Combination therapy with these newer agents and low-dose intramuscular hepatitis B immune globulin is likely to be the most cost effective hepatitis B immune globulin-containing regimen for the prevention of hepatitis B recurrence post-transplant. 5. Some form of hepatitis B virus prophylaxis needs be continued indefinitely post-transplant. However, the use of antivirals with very low rates of drug resistance will make it possible to stop hepatitis B immune globulin therapy in many patients currently receiving hepatitis B immune globulin/nucleos(t)ide combination therapy.
authors.affiliation: Victorian Liver Transplant Unit, Austin Health, Heidelberg, Victoria, Australia. peter.angus@austin.org.au
authors.forename: Peter W
authors.initials: PW
authors.lastname: Angus
authors.forename: Scott J
authors.initials: SJ
authors.lastname: Patterson
mesh_terms: D000998:Antiviral Agents / Q000008:administration & dosage*; D004359:Drug Therapy, Combination; D006509:Hepatitis B / Q000188:drug therapy / Q000601:surgery*; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000008:administration & dosage*; D007273:Injections, Intramuscular; D019259:Lamivudine / Q000008:administration & dosage*; D016031:Liver Transplantation
chemical_list: D000998:Antiviral Agents; D016756:Immunoglobulins, Intravenous; D019259:Lamivudine